Clinical trials located in

Marburg

Marburg city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Marburg, a city in Germany, is renowned for its rich history and picturesque architecture. It is home to the Philipps-Universität Marburg, one of the world’s oldest universities, founded in 1527. The city’s skyline is dominated by the Marburg Castle, which offers panoramic views and houses a museum detailing the region’s history. The Lahn River meanders through Marburg, adding to its charm. The city also played a significant role in the Brothers Grimm’s lives, who studied at its university. Marburg’s medieval old town, with its narrow streets and half-timbered houses, encapsulates its historical essence.

  • CT-EU-00117746

    Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    • Mabthera
    • Ifosfamide
    • Polatuzumab vedotin
    • Etoposide
    • Carboplatin
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    • Astegolimab
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Testing new medication treatment for Multiple System Atrophy

    This study is testing a drug called Movronersen (ION464) in adults with a disease called multiple system atrophy (MSA). The goal is to check whether this drug is safe to use and how the human body deals with it. The medicine will be given by injection into the space around the spinal cord. The first part of the study is to see if there are any problems with repeated doses. The second part will monitor the security of ION464 over a longer period of time. Scientists also want to see if the drug can affect a specific marker in the body, indicating that the drug is working. The first part will include screening (6 weeks), treatment (12 weeks) and then patient follow-up (24 weeks). In the second part, each person will be monitored for approximately 96 weeks, which includes a treatment period of 72 weeks and a follow-up period of 24 weeks.

    • Movronersen/ION464
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Examining combination treatment for Myelofibrosis

    This study is about testing a new combination of drugs known as KRT-232 (Navtemadlin) and TL-895 in patients with a blood disorder called Myelofibrosis. Doctors want to see how well this combination can work for patients who have tried other treatments without success, or those who can’t tolerate another medicine called JAK inhibitor. The first two groups will go through a process of adjusting doses to find the most tolerable and effective amount of medicine. The third group will be a larger set of patients, and this part of the trial will only continue if the treatment shows enough promise in the early stages. One of the ways to measure success is through a noticeable reduction in spleen size, measured by scans at 24 weeks. Doctors will also assess the patients’ symptoms using a special form.

    • Navtemadlin/KRT-232
    • TL-895- new potential medication for hematologic malignancies
  • Understanding Elinzanetant’s role in Menopause-related Sleep Issues

    The aim of this study is to investigate the use of a new drug called Elinzanetant for menopausal women who struggle with sleep problems. Menopause often causes sleep problems, such as waking up multiple times during the night, which can make life difficult. It may block proteins that cause sleep problems. The study will investigate whether Elinzanetant improves sleep compared with placebo. Researchers will look at how much time women spend awake after falling asleep at night and their total sleep time after 4 and 12 weeks of treatment. Women in the study will receive Elinzanetant or placebo for 12 weeks. The study will last approximately 22 weeks and includes check-ups including blood and urine tests, physical examinations, sleep tests and home recording of sleep quality and hot flashes. Any health problems that arise during the study will be recorded, whether they are related to the study drugs or not.

    • Elinzanetant
  • Testing new drug for lung fibrosis safety & effectiveness

    This study explores new treatment options for idiopathic pulmonary fibrosis (IPF) with a new drug called BMS-986278. The main goal is to thoroughly evaluate the effectiveness and safety of BMS-986278 in the treatment of IPF. During the study, participants will receive the drug under close supervision, allowing researchers to collect valuable data on its effects and potential benefits. This careful monitoring also ensures the safety and well-being of each participant. Participating in this study may provide insightful data on how IPF symptoms respond to this new treatment.

    • BMS-986278- new potential medication for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
  • Advancing treatment options for Idiopathic Pulmonary Fibrosis

    This clinical trial examines the effectiveness of BMS-986278 in people with Idiopathic Pulmonary Fibrosis (IPF). Involving over 1,000 participants, the trial is designed to assess the drug’s efficacy, safety, and tolerability. Participants will receive either the study drug or a placebo. Key measures include changes in lung function, quality of life, and exercise capacity. This research could offer important insights for treating IPF, a condition that affects lung tissue.

    • BMS-986278- new potential medication for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
  • Daprodustat treatment for pediatric anemia in chronic kidney disease

    This study is about examining a new medication, daprodustat, that will be used to treat low red blood cell count (anemia) which frequently occurs in kids and teenagers with chronic kidney disease. The study considers young patients aged between 3 months and 18 years, who are either on a dialysis treatment or not. The two parts of the study will be done separately, one with those who are on dialysis and another with those who are not. The study is expected to run for about 60 weeks and measures how the body processes the drug, its safety, and how it affects red blood cell levels.

    • Daprodustat
  • New treatment study for multiple system atrophy patients

    This study investigates TAK-341’s effectiveness in treating multiple system atrophy (MSA), a progressive neurological disorder. Around 138 participants will receive either TAK-341 or a placebo through regular intravenous infusions over 52 weeks. The trial primarily measures changes in the Unified Multiple System Atrophy Rating Scale Part I (UMSARS) to assess improvement in symptoms. This research is significant for understanding TAK-341’s potential in managing MSA, providing new insights into treatment options for this challenging condition.

    • TAK-341
  • Baxdrostat in resistant hypertension: safety and efficacy study

    This study is testing a medication named baxdrostat in people who have high blood pressure that can’t be controlled with their current medication. The study will compare people who are given baxdrostat daily with people who are given a placebo. The goal of the study is to find out if baxdrostat is safe to take and if it helps lower blood pressure. The study will look at the effects of 1 mg and 2 mg doses of baxdrostat on blood pressure. The study will also look at whether Baxdrostat helps reach a blood pressure reading below 130 mmHg.

    • Baxdrostat
  • Effects of new drug on metastatic prostate cancer

    This trial studies the effect of AZD5305 plus physician-chosen hormonal agents versus placebo in men with metastatic castration-sensitive prostate cancer (mCSPC). Around 1800 adult men with mCSPC are being enrolled and divided into two groups: those receiving AZD5305 and those receiving a placebo, both alongside standard hormonal treatments. Safety and treatment effects will be monitored. The goal is to find out if this new drug combination helps patients live longer without their cancer getting worse.

    • Darolutamide
    • Enzalutamide
    • Saruparib
    • Abiraterone Acetate

See more clinical trials in other cities in Germany:

.